Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ese and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD -G

Table 1

Amicus Therapeutics, Inc.

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

Period

from

February 4,

2002

(inception)

Three Months to

Ended March 31, March 31,

2007 2008 2008

Revenue:

Research revenue $- $2,466 $ 3,841

Collaboration revenue - 694 1,103

Total revenue - 3,160 4,944

Operating Expenses:

Research and development 7,085 6,941 96,819

General and administrative 2,850 5,186 43,256

Impairment
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 S&P Capital IQ (MHFI) ... Report coverage on MabVax Therapeutics Holdings Inc . ... clinical stage biotechnology company focused on the development of ... in the treatment of cancer. MabVax has discovered a ... protective immune responses generated by patients who have been ...
(Date:2/26/2015)... --  Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, today reported 2014 full year ... objectives, and financial guidance.  Synageva,s management team will ... EST to review the financial results and provide ... call by telephone, please dial (877) 445-4603 for ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension (MILE) ... technologies and awareness. The event is taking place from ... 21st 2015, in a live Google Hangout broadcast from ... of MILE, says, “Our lives are in our hands, ... Indefinite Life Extension is raising awareness about bio-sciences and ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... security to residences and private offices with their state-of-the-art fingerprint recognition ... schools and the military is now accessible to the public. ... ... biometric technology used to enhance Hollywood films like Mission Impossible is ...
... (Nasdaq: NLTX ), today announced that Peter Strumph, ... in the Biotech Industry,conference on Thursday, September 4, at ... York City. Mr. Strumph will provide a company,overview and ... The presentation will be webcast live and can ...
... a leader in health,care quality management solutions for ... approved the company as a vendor for the ... will automate the collection and submission of clinical,information ... to,hand-write data collection worksheets or manually enter data ...
Cached Biology Technology:BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices 2Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2MDdatacor Designated as Approved Vendor by CMS for Physician Quality Reporting Initiative 2
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... Adults fluent in English whose first language is ... to new research in the June 2 issue of ... who learn a second language in adolescence or later recall ... who conducted the study, Yan Jing Wu, PhD, and Guillaume ...
... The environmental engineering and Earth sciences department at ... from the U.S. Nuclear Regulatory Commission (NRC) to help ... Clemson is one of 16 U.S. universities to receive ... to boost nuclear education and expand the work force ...
... YORK, NY (June 1, 2010) The New York Stem ... NYSCF-Druckenmiller Fellows. These postdoctoral scientists join 15 accomplished stem ... the program since 2006. NYSCF has awarded 23 fellowships ... become one of the most competitive postdoctoral fellowship programs in ...
Cached Biology News:Second language learners recall native language when reading 2$400,000 NRC grant to develop nuclear engineering faculty at Clemson 2NYSCF awards fellowships to 8 innovative stem cell scientists 2NYSCF awards fellowships to 8 innovative stem cell scientists 3
... We deliversoluble protein or No Charge to ... best soluble protein results , 24 solubility ... , Powerful results on your most insoluble ... Service (SOS) uses proprietary tools and know-how ...
... provides a genome-wide microRNA (miRNA) expression profiling ... design, which enable highly sensitive and specific ... standard arrays for mature miRNA of all ... the Sanger miRBase database (Release 8.2). Our ...
... Peptide microarrays containing peptidomimetics built on ... on-chip synthesis platform. These microarrays are ... Custom Peptide Microarray Service. ... is completely customer specified. Thousands of ...
... peptide for OPA1-01009, OPEP-01009 is a 16 amino acid (amino ... fragmentation factor (DFF). The sequence of this peptide is ... K - S - V - K - L - ... P - R - K(18). This peptide may ...
Biology Products: